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BACKGROUND: The daily use of low-dose aspirin may be a safe, widely available, and inexpensive intervention for reducing the risk of pre-
term birth. Data on the potential side effects of low-dose aspirin use during pregnancy in low- and middle-income countries are needed.
OBJECTIVE: This study aimed to assess differences in unexpected emergency medical visits and potential maternal side effects from a ran-
domized, double-blind, multicountry, placebo-controlled trial of low-dose aspirin use (81 mg daily, from 6 to 36 weeks’ gestation).
STUDY DESIGN: This study was a secondary analysis of data from the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In
Nulliparas trial, a trial of the Global Network for Women’s and Children’s Health conducted in India (2 sites), Pakistan, Guatemala, Democratic
Republic of the Congo, Kenya, and Zambia. The outcomes for this analysis were unexpected emergency medical visits and the occurrence of the
following potential side effects—overall and separately—nausea, vomiting, rash or hives, diarrhea, gastritis, vaginal bleeding, allergic reaction,
and any other potential side effects. Analyses were performed overall and by geographic region.
RESULTS: Between the aspirin (n=5943) and placebo (n=5936) study groups, there was no statistically significant difference in the risk of unexpected
emergency medical visits or the risk of any potential side effect (overall). Of the 8 potential side effects assessed, only 1 (rash or hives) presented a different
risk by treatment group (4.2% in the aspirin group vs 3.5% in the placebo group; relative risk, 1.20; 95% confidence interval, 1.01−1.43; P=.042).
CONCLUSION: The daily use of low-dose aspirin seems to be a safe intervention for reducing the risk of preterm birth and well tolerated by
nulliparous pregnant women between 6 and 36 weeks’ gestation in low- and middle-income countries.
Key words: low- and middle-income countries, low-dose aspirin, potential side effects, pregnancy, preterm birth, safety, unexpected emer-
gency medical visits
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Introduction
Preterm birth, defined as birth before 37
weeks’ gestation, remains a major global
health issue. An estimated 15 million
babies are born preterm each year, and
this number is increasing.1 Globally,
preterm birth complications are the
leading cause of death among children
under 5 years of age, responsible for
approximately 1 million deaths each
year.2 Higher rates of preterm birth are
observed in low- and middle-income
countries (LMICs),3,4 where the average
preterm birth rate is 12% in LMICs
compared with 9% in higher-income
countries.1
Although the causes of preterm birth
are complex and vary across countries
and regions,5 there is evidence that low-
cost interventions may be universally
effective at reducing preterm births.6−9
A meta-analysis of previous low-dose
aspirin (LDA) trials that included
35,212 women reported a 9% reduction
in the rate of preterm birth.6 Studies in
high-income countries (United States,
Europe) have reported similar effects of
LDA on preterm birth, in those with a
high risk for preeclampsia.8,9 The Aspi-
rin Supplementation for Pregnancy
Indicated Risk Reduction In Nulliparas
(ASPIRIN) trial involving nearly 12,000
women from 6 LMICs reported a
reduced incidence of preterm delivery
among nulliparous women with single-
ton pregnancies who took daily LDA.7
Specifically, women taking daily LDA
were 11% less likely to deliver before the
completion of pregnancy at 37 weeks’
gestation, compared with women given
a placebo. In addition, there was a 25%
reduction in the rate of early preterm
birth (<34 weeks’ gestation).
Given the low cost of aspirin and its
widespread availability, adoption of
LDA to prevent preterm birth may be
warranted. However, to ensure gener-
alizability of the use of LDA, data on
the side effects of its use during preg-
nancy in LMICs are needed. Conse-
quently, this study aimed to assess the
risk of potential side effects and unex-
pected emergency medical visits associ-
ated with daily LDA use among
participants in the ASPIRIN trial.10 We
hypothesized that the risk of potential
side effects would not differ between the
LDA and placebo groups.
Materials and Methods
This study was a secondary analysis of
data from the ASPIRIN trial, a multina-
tional, randomized, double-blind, pla-
cebo-controlled trial, to assess the
efficacy of LDA (81 mg) administered
daily and initiated early in pregnancy
through 36 completed weeks for the
reduction of preterm birth. The ASPI-
RIN trial occurred at 7 community sites
in 6 countries (2 sites in India and 1 site
each in Pakistan, Zambia, the Demo-
cratic Republic of the Congo, Guate-
mala, and Kenya) between March 23,
2016, and April 11, 2019. Nulliparous
pregnant women aged 18 to 40 years
(women of younger ages in Africa were
permitted) and between 6 weeks and
0 days of pregnancy and 13 weeks and
6 days of pregnancy, confirmed by
ultrasound for dating, who resided in
the study areas were eligible to enroll in
this trial. The exclusion criteria included
a medical contraindication to aspirin,
previous prescription of aspirin for
more than 7 days during the pregnancy,
multiple gestation, more than 2 first-tri-
mester pregnancy losses, hemoglobin
levels of <7.0 g/dL at screening, systolic
blood pressure of ≥140 mm Hg and
diastolic blood pressure of ≥90 mm Hg
at screening, and other medical condi-
tions that might be considered a contra-
indication based on the judgment of the
site investigator. Eligible and consented
women were randomly assigned (1:1) to
receive aspirin or an identical-appearing
placebo. Participants were prescribed a
daily dose of 81 mg of aspirin or placebo
from the time of randomization to com-
pletion of 36 weeks’ gestation or the
time of delivery if delivery occurred
before that time. The study protocol
was approved by the relevant ethics
committees and regulatory agencies of
each country, including the ethics com-
mittees of the collaborators based in the
United States and that of the Research
Triangle Institute International. Written
informed consent for study participa-
tion was obtained from all participants.
The trial was registered with Clinical-
Trials.gov (NCT02409680) and the
Clinical Trials Registry-India (CTRI/
2016/05/006970). Additional study
details, including the study protocol,
have been previously published.7,10
Study sample
The population for this analysis
includes all randomized women who
consumed a dose of LDA (n=5943) or
placebo (n=5936) irrespective of the
amount of medication received or dura-
tion of treatment (safety population).
Data collection
Eligibility was determined by perform-
ing a brief physical examination,
reviewing medical history, and asking
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Why was this study conducted?
The daily use of low-dose aspirin (LDA) may be a safe, widely available, and
inexpensive intervention for reducing the risk of preterm birth. Data on the
potential side effects of LDA use during pregnancy in low- and middle-income
countries (LMICs) are needed.
Key findings
The daily use of (LDA) seems to be a safe intervention for reducing the risk of
preterm birth and well tolerated by nulliparous pregnant women between 6 and
36 weeks’ gestation in LMICs.
What does this add to what is known?
Our findings were consistent with trials of LDA initiated preconceptionally and
after the first trimester of pregnancy, which have shown a low incidence of
harm.
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about the use of other medicines or
medicinal products. Eligible partici-
pants were consented and randomized.
Participants met with study staff
biweekly. These visits included the
monitoring of potential side effects.
This process was continued until com-
pletion of 36 weeks’ gestation or until
an earlier delivery occurred. During this
same time frame, any unexpected or
emergency medical visits reported from
participants and/or documented in
medical records were also documented.
Demographic, clinical, and delivery
characteristics
Maternal demographic characteristics
were collected at study baseline and
included maternal age, number of previ-
ous pregnancies, gestational age at
enrollment, highest level of education,
and height and weight to calculate body
mass index. Pregnancy and delivery
characteristics included number of
antenatal care visits, type of delivery
attendant, delivery location, and deliv-
ery mode.
Outcomes
The primary outcomes for this analysis
included at least 1 unexpected emer-
gency medical visit (yes or no), at least 1
episode of any potential side effect (yes
or no), and at least 1 episode of the fol-
lowing potential side effects (yes or no)
—separately—nausea, vomiting, rash or
hives, diarrhea, gastritis, vaginal bleed-
ing, allergic reaction, and any other
potential side effects. Unexpected medi-
cal visit occurrences were obtained by
interview at scheduled biweekly visits
and by review of available medical
records. The presence or absence of
potential side effects were assessed by
interview at scheduled, biweekly visits.
Participants were asked directly whether
they had experienced any of the listed
symptoms since the previous biweekly
visit. Each response was read aloud to
the participant. The list of symptoms
was adapted from a listing used in a
similar trial.8 For the side effect of aller-
gic reaction, if the participant indicated
that she experienced an allergic reaction,
she was asked to specify if the reaction
was mild, severe, or anaphylactic. The
specific side effect linked to the allergic
reaction was not collected. Potential
side effects reported at an unexpected
emergency medical visit were excluded
from these outcomes as they would be
collected differentially across partici-
pants and sites. Secondary outcomes for
this analysis were the number of unex-
pected emergency visits, the number of
biweekly visits with any potential side
effect reported, and the number of
biweekly visits with each potential side
effect reported.
Statistical analysis
Demographic and baseline characteris-
tics were summarized by treatment
arm. Categorical variables were summa-
rized by frequency, normally distributed
continuous variables were summarized
by mean and standard deviation, and
nonnormally distributed continuous
variables were summarized as median
with 25th and 75th percentiles. Out-
comes were summarized by treatment
arm overall and by region.
Relative risks (RRs) and associated
95% confidence intervals (CI) of the
aspirin intervention compared with the
placebo intervention were obtained for
outcomes via generalized linear models
adjusting for site. The dichotomous
event models used a log link and bino-
mial distribution. The models for event
count outcomes used a log link and
Poisson distribution, offset by a log-
transformed number of visits to account
for the number of biweekly visits com-
pleted. In addition, the count outcome
models were subset to only include par-
ticipants with at least 1 episode of the
outcome. This subset allowed the
assessment of outcome burden among
those reporting any such events. In
addition, all models were run, including
geographic region (Africa, India, Paki-
stan, Guatemala) and the region by
treatment interaction to obtain region-
specific effect estimates. All data were
analyzed with Statistical Analysis Soft-
ware (version 9.4; SAS Institute, Cary,
NC). Because the analyses of these sec-
ondary ASPIRIN study outcomes were
exploratory in nature, no adjustment
for multiplicity was made.
Role of the funding source
Staff from the funder Eunice Kennedy
Shriver National Institute of Child
Health and Human Development
(NICHD) had input into the study
design, data interpretation, and
reviewed and approved this report.
Nonetheless, the authors’ views do not
necessarily represent those of the
NICHD. The corresponding author had
final responsibility for the decision to
submit for publication.
Results
A total of 11,879 participants were
included in this analysis; 97 participants
(47 in the aspirin group and 50 in the
placebo group) were excluded because
they were never exposed to a study
treatment (Figure). The proportion of
participants in each treatment arm was
distributed evenly; 50% (n=5943) were
in the aspirin arm and 50% (n=5936)
were in the placebo arm. Characteristics
of study participants are shown in
Table 1. Furthermore, 41% of the par-
ticipants were from India (Belagavi,
Nagpur); 31% were from Africa (Demo-
cratic Republic of the Congo, Zambia,
Kenya); 14% were from Pakistan; and
14% were from Guatemala. Most partic-
ipants were 20 to 29 years of age (59%),
had no previous pregnancy losses
(91%), and completed less than 13 years
of formal schooling (89%). The median
gestational age at enrollment was 10
weeks (range, 6−14), and the median
number of antenatal care visits was 4.
Nearly three-quarters of participants
delivered vaginally (72%), and more
than half delivered at a hospital (60%).
Characteristics were similar between
the aspirin and placebo study groups
(Table 1). As previously reported, 85%
of women were adherent (defined as
taking 90% or more of the medication
or placebo).7
A total of 11,736 (99%) participants
completed at least 1 biweekly safety
interview comprising a total of 147,565
separate interviews, and most partici-
pants (90%) completed 10 or more of
the maximum possible 15 biweekly vis-
its. In addition, 7349 unexpected medi-
cal visit interviews were conducted.
Among those who had at least 1
ajog.org Original Research
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unexpected visit, most participants
(55%) had only the 1 unexpected visit,
78% to 79% had 1 or 2 unexpected visits
(range, 1−9 for both treatment groups).
Among participants, one-third (34%)
had at least 1 unexpected visit, and
about one-half (49%) had at least 1
potential side effect during the study
period (Table 2). The most common
reported potential side effects among all
participants were nausea and vomiting.
Among all participants, 29% had at least
1 episode of nausea, and 27% had at
least 1 episode of vomiting. In addition,
more than a quarter of participants
(28%) reported at least 1 episode of an
“other” potential side effect. The most
common “other” side effects reported
were cold/cough, fever, abdominal pain
or discomfort, and headache.
Between the aspirin and placebo
study groups, there was no significant
difference in the risk of unexpected
medical visit. Of the 8 potential side
effects assessed, only 1 (rash or hives)
presented a difference in risk by treat-
ment group (4.2% in the aspirin group
vs 3.5% in the placebo group RR, 1.20;
95% CI, 1.01−1.43; P=.042).
We observed an interaction between
region and treatment for the risk of par-
ticipants having at least 1 episode of an
unexpected medical visit and at least 1
episode of rash or hives (P=.002 and
P=.007, respectively); Table 3. For par-
ticipants in the African sites, those in
the aspirin group were at greater risk of
unexpected medical visits (RR, 1.25;
95% CI, 1.09−1.43) and rash or hives
(RR, 2.18; 95% CI, 1.25−3.80). Con-
versely, for these same outcomes, par-
ticipants in the Guatemalan site in the
aspirin group were at lower risk of
experiencing unexpected medical visits
(RR, 0.74; 95% CI, 0.57−0.95) and rash
or hives (RR, 0.58; 95% CI, 0.34−0.99).
All other regions observed no difference
in risk for these outcomes, and no other
outcome had a significant interaction of
region and treatment (Tables 3 and 4).
Discussion
Principal findings
In this ethnically and geographically
diverse population of nearly 12,000 nul-
liparous women with a singleton preg-
nancy, daily LDA use initiated in early
pregnancy was associated with no or
minimal risk as assessed by unexpected
medical visits and potential side effects.
There was no increase in risk other than
a 20% increase in the incidence of rash
or hives among the LDA group. None
of the rashes or hives were serious or
led to hospitalization or urgent medical
care. Findings suggest that daily use of
LDA is a safe intervention for reducing
the risk of preterm birth and well toler-
ated by nulliparous pregnant women in
LMICs.
Results
These findings are consistent with trials
of LDA initiated preconceptionally11
after the first trimester of pregnancy,12
which have shown a low incidence of
harm. The safety of LDA use in our
study population is further supported
by the lack of a treatment effect
observed in serious adverse events
occurring in the ASPIRIN trial. Specifi-
cally, LDA use was not associated with
major maternal (eg, bleeding complica-
tions, mortality) or fetal and neonatal
(eg, fetal loss, neonatal death, congenital
abnormalities) adverse events in the
ASPIRIN trial.7
Strengths and limitations
Generalizability of our findings to gen-
eral obstetrical populations may be lim-
ited because we enrolled only
nulliparous women with singleton preg-
nancies in LMICs. Data collection for
outcomes included in this analysis were
limited to those occurring during preg-
nancy. Detailed information on reasons
for unexpected emergency medical vis-
its was not collected, and visits may not
have been related to LDA use or preg-
nancy. Data pertaining to long-term
infant outcomes associated with in
utero aspirin exposure were not col-
lected. Follow-up data from a previous
study showed no increased risk in
adverse outcomes among infants
exposed in utero.12 Despite these
FIGURE
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TABLE 1
Baseline demographic and site of delivery characteristics: Aspirin Supplementation for Pregnancy Indicated
Risk Reduction In Nulliparas trial
Variable Total (N=11,879) Aspirin (n=5943) Placebo (n=5936)
Maternal age (y)
<20 4636 (39) 2299 (39) 2337 (39)
20−29 6977 (59) 3514 (59) 3463 (58)
>29 266 (2) 130 (2) 136 (2)
Number of previous pregnancies not resulting in delivery
0 10,780 (91) 5412 (91) 5368 (90)
1 950 (8) 466 (8) 484 (8)
2 149 (1) 65 (1) 84 (1)
Gestational age at enrollment (wk) 10.1 (8.6−12.0) 10.0 (8.6−12.0) 10.1 (8.6−12.0)
Maternal education
No formal schooling 1743 (15) 874 (15) 869 (15)
1−6 y of schooling 1757 (15) 875 (15) 882 (15)
7−12 y of schooling 7085 (60) 3546 (60) 3539 (60)
≥13 y of schooling 1292 (11) 647 (11) 645 (11)
Maternal height (cm) 153.1 (7.0) 153.1 (6.9) 153.1 (7.0)
Maternal weight (kg) 49.2 (8.9) 49.3 (9.0) 49.2 (8.7)
Maternal BMI (kg/m2) 21.0 (3.8) 21.0 (3.8) 21.0 (3.7)
Antenatal care visits 5 (4−6) 5 (4−6) 5 (4−6)
Delivery attendant
Physician 5947 (50) 2991 (50) 2956 (50)
Nurse or nurse midwife 4509 (38) 2255 (38) 2254 (38)
Traditional birth attendant 947 (8) 472 (8) 475 (8)
Family, self, or other 430 (4) 208 (4) 222 (4)
Delivery location
Hospital 7077 (60) 3535 (60) 3542 (60)
Clinic or health center 3625 (31) 1836 (31) 1789 (30)
Home or other 1135 (10) 557 (9) 578 (10)
Delivery mode
Vaginal 8573 (72) 4252 (72) 4321 (73)
Cesarean delivery 2962 (25) 1523 (26) 1439 (24)
Miscarriage 236 (2) 112 (2) 124 (2)
MTP 66 (1) 41 (1) 25 (<1)
Site
DRC 1361 (11) 678 (11) 683 (12)
Zambia 1008 (8) 502 (8) 506 (9)
Guatemala 1701 (14) 850 (14) 851 (14)
Belagavi, India 2750 (23) 1375 (23) 1375 (23)
Pakistan 1625 (14) 821 (14) 804 (14)
Nagpur, India 2068 (17) 1036 (17) 1032 (17)
Kenya 1366 (11) 681 (11) 685 (12)
Data are presented as number (percentage), median (Q1−Q3), or median (standard deviation).
BMI, body mass index; DRC, Democratic Republic of the Congo; MTP, medical termination of pregnancy.
Short. Aspirin safety during pregnancy in low- and middle-income countries. Am J Obstet Gynecol Glob Rep 2021.
ajog.org Original Research
February 2021 AJOG Global Reports 5
TABLE 2
Unexpected medical visit and potential side effects: Aspirin Supplementation for Pregnancy Indicated Risk
Reduction In Nulliparas trial
Variable Total (N=11,879) Aspirin (n=5943) Placebo (n=5936) RR (95% CI) P value
Unexpected emergency medical visit
At least 1 unexpected emergency medical visit 3989 (33.6) 2015 (33.9) 1974 (33.3) 1.02 (0.98−1.06) .247
Number of unexpected medical visits 1 (1−2) 1 (1−2) 1 (1−2) 0.97 (0.93−1.02) .223
Biweekly monitoring of potential side effects
Any potential side effect
At least 1 episode 5857 (49.3) 2947 (49.6) 2910 (49.0) 1.00 (0.98−1.03) .804
Number of potential side effects, median 3 (1−7) 3 (1−7) 3 (1−6) 0.98 (0.95−1.00) .040
Nausea
At least 1 episode 3402 (28.6) 1691 (28.5) 1711 (28.8) 0.98 (0.94−1.03) .505
Number of episodes 2 (1−3) 2 (1−3) 2 (1−3) 1.01 (0.97−1.05) .679
Vomiting
At least 1 episode 3198 (26.9) 1587 (26.7) 1611 (27.1) 0.99 (0.94−1.04) .641
Number of episodes 2 (1−3) 2 (1−3) 2 (1−3) 0.99 (0.95−1.04) .677
Rash or hives
At least 1 episode 458 (3.9) 251 (4.2)a 207 (3.5)a 1.20 (1.01−1.43)a .042a
Number of episodes 1 (1−2) 1 (1−2) 1 (1−2) 0.97 (0.83−1.13) .674
Diarrhea
At least 1 episode 877 (7.4) 452 (7.6) 425 (7.2) 1.06 (0.94−1.20) .342
Number of episodes 1 (1−1) 1 (1−1) 1 (1−1) 0.94 (0.83−1.05) .279
Gastritis
At least 1 episode 1752 (14.7) 853 (14.4) 899 (15.1) 0.94 (0.87−1.02) .149
Number of episodes 1 (1−2) 1 (1−2) 1 (1−2) 0.97 (0.91−1.04) .406
Vaginal bleeding
At least 1 episode 457 (3.8) 214 (3.6) 243 (4.1) 0.88 (0.73−1.05) .150
Number of episodes 1 (1−1) 1 (1−1) 1 (1−1) 1.03 (0.86−1.22) .778
Allergic reaction
At least 1 episode 45 (0.4) 22 (0.4) 23 (0.4) 0.96 (0.53−1.71) .882
Number of episodes 1 (1−1) 1 (1−1) 1 (1−1) 0.99 (0.57−1.73) .982
Other potential side effect
At least 1 episode 3313 (27.9) 1673 (28.2) 1640 (27.6) 1.01 (0.97−1.06) .611
Number of episodes 2 (1−3) 2 (1−3) 2 (1−3) 0.99 (0.95−1.04) .696
Data are presented as number (percentage) or median (25th percentile−75th percentile). Unexpected emergency medical visits may have been related to potential side effects but are analyzed sepa-
rately from potential side effects reported at biweekly visits. For “at least 1” variables, the denominator is any participant included in the safety population, and the numerator is participants with at least
1 report of the event. For “number of” variables, the denominator is any participant included in the safety population who experienced at least 1 episode of that specific event, and the numerator is the
number of events of that specific type experienced by the participant. In addition, the “number of” RR models have been adjusted for the number of biweekly visits completed (range, 1−16). The most
commonly reported other potential side effects include cold/cough or fever, abdominal pain or discomfort, and headache.
CI, confidence interval; RR, relative risk.
a P<.05.
Short. Aspirin safety during pregnancy in low- and middle-income countries. Am J Obstet Gynecol Glob Rep 2021.
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TABLE 3
Unexpected medical visits and potential side effects by region: Aspirin Supplementation for Pregnancy Indi-
cated Risk Reduction In Nulliparas trial
Variable Int P value Total (n=11,879) Africa (n=3735) India (n=4818) Pakistan (n=1625) Guatemala (n=1701)
Participants with at least 1 unexpected
emergency medical visit, RR (95% CI)
.002 0.98 (0.90−1.06) 1.25 (1.09−1.43) 1.00 (0.94−1.06) 0.99 (0.88−1.11) 0.74 (0.57−0.95)
Aspirin 2015/5943 (33.9) 368/1861 (19.8) 1228/2411 (50.9) 330/821 (40.2) 89/850 (10.5)
Placebo 1974/5936 (33.3) 297/1874 (15.8) 1228/2407 (51.0) 328/804 (40.8) 121/851 (14.2)
Biweekly monitoring of potential side
effects
Participants with at least 1 potential side
effect, RR (95% CI)
.423 1.01 (0.97−1.06) 1.06 (0.97−1.17) 0.99 (0.94−1.03) 1.03 (0.97−1.08) 0.98 (0.85−1.12)
Aspirin 2947/5943 (49.6) 625/1861 (33.6) 1434/2411 (59.5) 625/821 (76.1) 263/850 (30.9)
Placebo 2910/5936 (49.0) 591/1874 (31.5) 1452/2407 (60.3) 597/804 (74.3) 270/851 (31.7)
Participants with at least 1 episode of
nausea, RR (95% CI)
.927 0.99 (0.92−1.06) 1.00 (0.85−1.17) 0.97 (0.89−1.04) 1.00 (0.93−1.09) 0.99 (0.80−1.22)
Aspirin 1691/5943 (28.5) 252/1861 (13.5) 817/2411 (33.9) 482/821 (58.7) 140/850 (16.5)
Placebo 1711/5936 (28.8) 255/1874 (13.6) 844/2407 (35.1) 470/804 (58.5) 142/851 (16.7)
Participants with at least 1 episode of
vomiting, RR (95% CI)
.295 0.94 (0.86−1.03) 0.94 (0.78−1.13) 0.97 (0.90−1.05) 1.05 (0.96−1.15) 0.81 (0.61−1.09)
Aspirin 1587/5943 (26.7) 199/1861 (10.7) 881/2411 (36.5) 434/821 (52.9) 73/850 (8.6)
Placebo 1611/5936 (27.1) 213/1874 (11.4) 903/2407 (37.5) 405/804 (50.4) 90/851 (10.6)
Participants with at least 1 episode of rash
or hives, RR (95% CI)
.007 1.19 (0.95−1.47) 2.18 (1.25−3.80) 1.33 (0.96−1.84) 1.16 (0.90−1.51) 0.58 (0.34−0.99)
Aspirin 251/5943 (4.2) 39/1861 (2.1) 84/2411 (3.5) 107/821 (13.0) 21/850 (2.5)
Placebo 207/5936 (3.5) 18/1874 (1.0) 63/2407 (2.6) 90/804 (11.2) 36/851 (4.2)
Participants with at least 1 episode of
diarrhea, RR (95% CI)
.919 1.05 (0.91−1.23) 1.15 (0.85−1.55) 1.06 (0.89−1.26) 0.98 (0.69−1.40) 1.03 (0.73−1.46)
Aspirin 452/5943 (7.6) 88/1861 (4.7) 246/2411 (10.2) 56/821 (6.8) 62/850 (7.3)
Placebo 425/5936 (7.2) 77/1874 (4.1) 232/2407 (9.6) 56/804 (7.0) 60/851 (7.1)
Participants with at least 1 episode of
gastritis, RR (95% CI)
.380 0.99 (0.89−1.10) 1.07 (0.84−1.36) 0.91 (0.80−1.02) 0.90 (0.76−1.05) 1.10 (0.84−1.44)
Aspirin 853/5943 (14.4) 124/1861 (6.7) 415/2411 (17.2) 214/821 (26.1) 100/850 (11.8)
Placebo 899/5936 (15.1) 117/1874 (6.2) 457/2407 (19.0) 234/804 (29.1) 91/851 (10.7)
Participants with at least 1 episode of
vaginal bleeding, RR (95% CI)
.349 0.83 (0.69−1.02) 1.05 (0.71−1.54) 0.92 (0.69−1.21) 0.85 (0.59−1.24) 0.59 (0.36−0.98)
Aspirin 214/5943 (3.6) 52/1861 (2.8) 91/2411 (3.8) 48/821 (5.8) 23/850 (2.7)
Placebo 243/5936 (4.1) 50/1874 (2.7) 99/2407 (4.1) 55/804 (6.8) 39/851 (4.6)
Participants with at least 1 episode of
allergic reaction, RR (95% CI)
.823 0.84 (0.39−1.78) 1.34 (0.47−3.86) 0.75 (0.26−2.15) 0.49 (0.04−5.39) 1.00 (0.35−2.84)
Aspirin 22/5943 (0.4) 8/1861 (0.4) 6/2411 (0.2) 1/821 (0.1) 7/850 (0.8)
Placebo 23/5936 (0.4) 6/1874 (0.3) 8/2407 (0.3) 2/804 (0.2) 7/851 (0.8)
Participants with at least 1 episode of
other potential side effect, RR (95% CI)
.677 1.03 (0.94−1.13) 1.10 (0.95−1.28) 1.00 (0.94−1.07) 0.98 (0.86−1.12) 1.03 (0.76−1.39)
Aspirin 1673/5943 (28.2) 305/1861 (16.4) 1013/2411 (42.0) 277/821 (33.7) 78/850 (9.2)
Placebo 1640/5936 (27.6) 279/1874 (14.9) 1008/2407 (41.9) 277/804 (34.5) 76/851 (8.9)
Data are presented number/total number (percentage), unless otherwise specified. Unexpected emergency medical visits may have been related to potential side effects but are analyzed separately
from potential side effects reported at biweekly visits. The denominator is any participant included in the safety population, and the numerator is participants with at least 1 report of the event. The
most commonly reported other potential side effects include cold/cough or fever, abdominal pain or discomfort, and headache.
CI, confidence interval; Int, interaction; RR, relative risk.
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TABLE 4
Unexpected medical visit and potential side effects counts by region: Aspirin Supplementation for Pregnancy
Indicated Risk Reduction In Nulliparas trial
Variable Int P value Total (n=11,879) Africa (n=3735) India (n=4818) Pakistan (n=1625) Guatemala (n=1701)
Number of unexpected emergency medical
visit, RR (95% CI)
.785 0.96 (0.89−1.04) 1.01 (0.88−1.16) 0.99 (0.93−1.04) 0.94 (0.84−1.06) 0.91 (0.70−1.18)
Aspirin 1 (1−2) 1 (1−1) 2 (1−3) 1 (1−2) 1 (1−1)
Placebo 1 (1−2) 1 (1−1) 2 (1−3) 1 (1−2) 1 (1−1)
Biweekly monitoring of potential side
effects
Number of potential side effects, RR (95%
CI)
.003 0.96 (0.93−0.99) 0.98 (0.91−1.06) 1.01 (0.98−1.04) 0.92 (0.87−0.96) 0.93 (0.85−1.02)
Aspirin 3 (1−7) 2 (1−3) 4 (2−8) 4 (2−8) 2 (1−3)
Placebo 3 (1−6) 2 (1−3) 4 (2−8) 4 (2−9) 2 (1−4)
Number of episodes of nausea, RR (95% CI) .092 0.99 (0.93−1.05) 1.04 (0.90−1.20) 1.06 (0.99−1.12) 0.95 (0.88−1.02) 0.90 (0.76−1.08)
Aspirin 2 (1−3) 1 (1−2) 2 (1−3) 2 (1−4) 1 (1−2)
Placebo 2 (1−3) 1 (1−2) 2 (1−3) 2 (1−4) 1 (1−2)
Number of episodes of vomiting, RR (95%
CI)
.192 0.98 (0.91−1.06) 1.09 (0.93−1.28) 1.01 (0.96−1.08) 0.93 (0.85−1.01) 0.91 (0.72−1.16)
Aspirin 2 (1−3) 1 (1−2) 2 (1−3) 2 (1−3) 1 (1−2)
Placebo 2 (1−3) 1 (1−2) 2 (1−3) 2 (1−4) 1 (1−2)
Number of episodes of rash or hives, RR
(95% CI)
.841 1.00 (0.83−1.21) 0.98 (0.60−1.60) 0.97 (0.73−1.29) 0.91 (0.73−1.14) 1.15 (0.74−1.79)
Aspirin 1 (1−2) 1 (1−1) 1 (1−1) 1 (1−2) 1 (1−2)
Placebo 1 (1−2) 1 (1−1) 1 (1−1) 1 (1−2) 1 (1−2)
Number of episodes of diarrhea, RR (95%
CI)
.902 0.96 (0.83−1.10) 0.94 (0.71−1.23) 0.91 (0.78−1.06) 0.95 (0.68−1.34) 1.04 (0.76−1.40)
Aspirin 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1)
Placebo 1 (1−1) 1 (1−1) 1 (1−2) 1 (1−1) 1 (1−1)
Number of episodes of gastritis, RR (95%
CI)
.840 0.97 (0.89−1.05) 0.94 (0.75−1.18) 0.99 (0.90−1.09) 0.93 (0.81−1.06) 1.01 (0.83−1.23)
Aspirin 1 (1−2) 1 (1−1) 1 (1−2) 1 (1−2) 1 (1−3)
Placebo 1 (1−2) 1 (1−1) 1 (1−2) 1 (1−2) 1 (1−2)
Number of episodes of vaginal bleeding, RR
(95% CI)
.599 1.02 (0.84−1.24) 1.08 (0.74−1.57) 0.93 (0.71−1.22) 1.23 (0.86−1.75) 0.88 (0.54−1.45)
Aspirin 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1)
Placebo 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1)
Number of episodes of allergic reaction, RR
(95% CI)
.945 1.04 (0.50−2.16) 0.94 (0.36−2.45) 0.85 (0.32−2.24) 1.12 (0.10−12.41) 1.29 (0.48−3.45)
Aspirin 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1) 1 (1−1)
Placebo 1 (1−1) 1 (1−2) 1 (1−2) 1 (1−1) 1 (1−1)
Number of episodes of other potential side
effect, RR (95% CI)
.080 0.95 (0.88−1.04) 0.95 (0.83−1.09) 1.03 (0.97−1.08) 0.87 (0.77−0.98) 0.98 (0.76−1.28)
Aspirin 2 (1−3) 1 (1−2) 2 (1−4) 1 (1−2) 1 (1−1)
Placebo 2 (1−3) 1 (1−2) 2 (1−3) 1 (1−3) 1 (1−2)
Data are presented as median (25th percentile−75th percentile), unless otherwise specified. Unexpected emergency medical visits may have been related to potential side effects but are analyzed
separately from potential side effects reported at biweekly visits. The denominator is any participant included in the safety population who experienced at least 1 episode of that specific event, and the
numerator is the number of events of that specific type experienced by the participant. In addition, the RR models have been adjusted for the number of biweekly visits completed (range, 1−16). The
most commonly reported other potential side effects include cold/cough or fever, abdominal pain or discomfort, and headache.
CI, confidence interval; Int, interaction; RR, relative risk.
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limitations, our study has several
strengths, most notably the use of data
from a randomized, controlled clinical
trial. High-quality data regarding unex-
pected medical visits and potential side
effects were obtained biweekly through-
out the trial, including more than
154,900 data collection opportunities.
The study sample was large and diverse
and represented women from 6 LMICs.
Conclusion
This study adds important informa-
tion to the literature regarding LDA
use during pregnancy in LMICs. The
results of the ASPIRIN trial have
shown that LDA given to nulliparous
women from LMICs beginning early
in pregnancy reduces the rate of pre-
term birth.7 Our supplementary find-
ings have shown that this therapy is
safe and tolerated well. Because treat-
ment with LDA is low cost and avail-
able in LMICs, it is an ideal candidate
for implementation in these environ-
ments. Given the high and increasing
rate of preterm birth in LMICs, LDA
use during pregnancy seems to be a
low-risk intervention that could have
major benefits. &
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